Evidence map›Paper›PMID 36759749›Full record

ArticlePediatric research2023

Premature infants born <28 weeks with acute kidney injury have increased bronchopulmonary dysplasia rates.

Michelle C Starr, Robert H Schmicker, Brian A Halloran, Patrick Heagerty, Patrick Brophy, Stuart L Goldstein, Sandra E Juul, Sangeeta Hingorani, David J Askenazi, PENUT Trial Consortium

Open access · greenAbstract read
In one paragraph

Article in Pediatric research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Michelle C StarrDivision of Pediatric Nephrology, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA. mcstarr@iu.edu.
Robert H SchmickerDepartment of Biostatistics, University of Washington, Seattle, WA, USA.
Brian A HalloranDivision of Pediatric Nephrology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA.
Patrick HeagertyDepartment of Biostatistics, University of Washington, Seattle, WA, USA.
Patrick BrophyUniversity of Rochester and Golisano Children's Hospital, Rochester, NY, USA.
Stuart L GoldsteinPediatric Nephrology & Hypertension, Department of Pediatrics, Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Sandra E JuulDepartment of Pediatrics, Seattle Children's Hospital and University of Washington, Seattle, WA, USA.
Sangeeta Hingorani *Department of Pediatrics, Seattle Children's Hospital and University of Washington, Seattle, WA, USA.
David J Askenazi *Division of Pediatric Nephrology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA.
PENUT Trial Consortium
University of Washington · USUniversity of Alabama at Birmingham · USCincinnati Children's Hospital Medical Center · USGolisano Children's Hospital · USIndiana University – Purdue University Indianapolis · USSeattle Children's Hospital · US

Funding

Transform Dissemination and Implementation Science in CTSA ProgramsUL1TR002319 · NCATS · UNIVERSITY OF WASHINGTON · PI John K. Amory · 2017 to 2026
$100.0M
Preterm Epo Neuroprotection Trial (PENUT Trial) CCCU01NS077953 · NINDS · UNIVERSITY OF WASHINGTON · PI JUUL, SANDRA E · 2013 to 2018
$10.7M
Recombinant Erythropoietin for Protection of Infant Renal Disease(REPAIReD)R01DK103608 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · PI ASKENAZI, DAVID JOSEPH, GOLDSTEIN, STUART L · 2014 to 2019
$3.0M
Preterm Epo Neuroprotection Trial (PENUT Trial) DCCU01NS077955 · NINDS · UNIVERSITY OF WASHINGTON · PI HEAGERTY, PATRICK J · 2013 to 2018
$1.5M
Phase 2 Study of Selective Cytopheretic Device for the Treatment of Pediatric Patients with Acute Kidney Injury R01FD005092 · FDA · INNOVATIVE BIOTHERAPIES, INC. · PI GOLDSTEIN, STUART L, HUMES, H. DAVID · 2015 to 2018
$976k
Acute Renal Injury Sequelae in NICU Graduates (ARISING)U34DK117128 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AMBALAVANAN, NAMASIVAYAM, ASKENAZI, DAVID JOSEPH · 2019 to 2020
$754k
FDA HHS R01 FD005092NCATS NIH HHS UL1 TR002319NIDDK NIH HHS R01 DK103608NIDDK NIH HHS U34 DK117128NINDS NIH HHS U01 NS077953NINDS NIH HHS U01 NS077955
6 · The paper itself

Abstract

backgroundDespite a growing understanding of bronchopulmonary dysplasia (BPD) and advances in management, BPD rates remain stable. There is mounting evidence that BPD may be due to a systemic insult, such as acute kidney injury (AKI). Our hypothesis was that severe AKI would be associated with BPD.

methodsWe conducted a secondary analysis of premature infants [24-27 weeks gestation] in the Recombinant Erythropoietin for Protection of Infant Renal Disease cohort (N = 885). We evaluated the composite outcome of Grade 2/3 BPD or death using generalized estimating equations. In an exploratory analysis, urinary biomarkers of angiogenesis (ANG1, ANG2, EPO, PIGF, TIE2, FGF, and VEGFA/D) were analyzed.

results594 (67.1%) of infants had the primary composite outcome of Grade 2/3 BPD or death. Infants with AKI (aOR: 1.69, 95% CI: 1.16-2.46) and severe AKI (aOR: 2.05, 95% CI: 1.19-3.54). had increased risk of the composite outcome after multivariable adjustment Among 106 infants with urinary biomarkers assessed, three biomarkers (VEGFA, VEGFD, and TIE2) had AUC > 0.60 to predict BPD.

conclusionsInfants with AKI had a higher likelihood of developing BPD/death, with the strongest relationship seen in those with more severe AKI. Three urinary biomarkers of angiogenesis may have potential to predict BPD development. IMPACT: AKI is associated with lung disease in extremely premature infants, and urinary biomarkers may predict this relationship. Infants with AKI and severe AKI have higher odds of BPD or death. Three urinary angiogenesis biomarkers are altered in infants that develop BPD. These findings have the potential to drive future work to better understand the mechanistic pathways of BPD, setting the framework for future interventions to decrease BPD rates. A better understanding of the mechanisms of BPD development and the role of AKI would have clinical care, cost, and quality of life implications given the long-term effects of BPD.

Indexed as

Acute Kidney InjuryBronchopulmonary DysplasiaBiomarkersFemaleHumansInfantInfant, Extremely PrematureInfant, NewbornPlacenta Growth FactorQuality of LifeBiomarkersPlacenta Growth Factor

Identifiers

PMID36759749
PMCPMC10403374
OpenAlexW4319826864

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.